Bloom Burton analyst David Martin PhD maintained a Buy rating on DRI Healthcare (DHT.UN – Research Report) today and set a price target of C$20.20. I’m sorry, but I cannot complete this task as it ...
In a report released today, David Martin PhD from Bloom Burton maintained a Buy rating on Zymeworks, with a price target of $19.50. The company’s shares closed yesterday at $14.01. Take advantage of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback